Related Experiment Video
Updated: May 12, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Controversies in thromboprophylaxis: a focus on nonsurgical patients
Rachel E Clapham1, Christoph Mueller2, Jecko Thachil3
1King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK; Institute of Pharmaceutical Sciences, King's College London, London, UK.
None:
Hospital-associated venous thromboembolism (VTE) remains a major patient safety issue globally. Guidance documents recommend the use of risk-assessment models to determine risk of VTE, with thromboprophylaxis offered to those at high risk. Implementation of such guidance with a systematic approach has been demonstrated to reduce hospital-associated VTE. However, there remain areas of controversy with differing recommendations across guidelines and a lack of high-quality supporting evidence in some patient groups. In this review, we explore some of these issues using 3 case scenarios. The first case is a patient with obesity admitted to hospital for management of pneumonia in whom we explore variations in VTE risk assessment outcome, dosing of thromboprophylaxis in obesity, and the role of postdischarge thromboprophylaxis. In the second case, the approach to VTE prevention in a hospitalized patient with known cirrhosis and longstanding thrombocytopenia is discussed. The final case involves management of a patient with an acute psychiatric illness and VTE risk factors.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins